Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib plus fulvestrant versus placebo plus fulvestrant in HR-positive, HER2-negative metastatic breast cancer
jRCT2080222543Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jun 2014
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Palbociclib + fulvestrant ± goserelin with Placebo + fulvestrant ± goserelin (2 arms). Primary endpoint: Progression-free survival (PFS). Started Jun 2014; status: completed.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080222543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222543.